India Equity Analyst - Fundamental & Thematic, Beat the Street

Sudarshan Bhandari

India Equity Analyst - Fundamental & Thematic

Beat the Street

Beat The Street was founded by Nimish Maheshwari and Sudarshan Bhandari, both of whom are Chartered Accountants by Profession, known for their expert analysis in the fields of Business, Sectoral analysis, and Corporate governance.

With a strong social media presence of 45,000+ Subscribers across various platforms, they are considered trusted voices in the industry. Their insights and analysis have been featured in some of India’s most prominent publications, including the Economic Times, Dalal Street Investment Journal, The Morning Context, and The Ken.

Their analysis on Bankrupt & Insolvent companies has been instrumental in saving investors from significant losses. They have a keen eye for identifying red flags and has identified exclusive redflags earlier in Vedanta, Nykaa, Dhani Services, Adani and many more.

Read Business Not Stock Prices

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/innova-captab-ltd" target="_blank" data-smartkarma-citation="entities:36109:1" rel="noopener">Innova Captab (1605221D IN)</a> achieved strong Q4 FY25 revenue growth of nearly 20%, though profitability felt impact from new Jammu plant's depreciation and finance costs.</li>
<li>The new manufacturing facility in Jammu was commercialized in Q4 FY25, contributing INR  36 crores revenue and expanding production capabilities.</li>
<li>The company expects strong FY26 growth, with Jammu plant adding INR 400 crores, projecting a 25% revenue CAGR long-term and improving margins.</li>
</ul>



Innova Captab (1605221D IN) achieved strong Q4 FY25 revenue growth of nearly 20%, though profitability felt impact from new Jammu plant's depreciation and finance costs.
The new manufacturing facility in Jammu was commercialized in Q4 FY25, contributing INR  36 crores revenue and expanding production capabilities.
The company expects strong FY26 growth, with Jammu plant adding INR 400 crores, projecting a 25% revenue CAGR long-term and improving margins.


Innova Captab Q4FY25 Update: Jammu Plant, R&D, and Market Penetration

<ul>
<li>
<a href="https://www.smartkarma.com/entities/innova-captab-ltd" target="_blank" data-smartkarma-citation="entities:36109:1" rel="noopener">Innova Captab (1605221D IN)</a> has commissioned a new 11-acre manufacturing facility in Jammu, with capacity for 10.7 bn tablets and 562 mn LVP/respules.</li>
<li>The plant adds new dosage forms and therapy areas (Penicillin, Penum) and enables strategic domestic-export capacity balancing, with potential ROIC &gt;20%.</li>
<li>This is not just a capacity bump, it positions Innova for premium exports, higher utilization, and long-term revenue scale-up to INR 14–16Bn from Jammu alone.</li>
</ul>



Innova Captab (1605221D IN) has commissioned a new 11-acre manufacturing facility in Jammu, with capacity for 10.7 bn tablets and 562 mn LVP/respules.
The plant adds new dosage forms and therapy areas (Penicillin, Penum) and enables strategic domestic-export capacity balancing, with potential ROIC &gt;20%.
This is not just a capacity bump, it positions Innova for premium exports, higher utilization, and long-term revenue scale-up to INR 14–16Bn from Jammu alone.


<ul>
<li>
<a href="https://www.smartkarma.com/entities/innova-captab-ltd" target="_blank" data-smartkarma-citation="entities:36109:1" rel="noopener">Innova Captab (1605221D IN)</a>’s Q3 FY25 results show modest revenue growth, enhanced EBITDA margins, and a significant manufacturing expansion via the new Jammu facility with innovative dosage forms.</li>
<li>Improved margins and strategic expansion into new dosage forms enhance competitiveness, setting the stage for 25%+ growth and long-term profitability in the evolving CDMO and generics market.</li>
<li>The company anticipates Rs. 400 to Rs. 500 crores of incremental revenue from the Jammu facility in the next fiscal year.</li>
</ul>



Innova Captab (1605221D IN)’s Q3 FY25 results show modest revenue growth, enhanced EBITDA margins, and a significant manufacturing expansion via the new Jammu facility with innovative dosage forms.
Improved margins and strategic expansion into new dosage forms enhance competitiveness, setting the stage for 25%+ growth and long-term profitability in the evolving CDMO and generics market.
The company anticipates Rs. 400 to Rs. 500 crores of incremental revenue from the Jammu facility in the next fiscal year.


<ul>
<li>
<a href="https://www.smartkarma.com/entities/innova-captab-ltd" target="_blank" data-smartkarma-citation="entities:36109:1" rel="noopener">Innova Captab (1605221D IN)'</a>s New Jammu facility to be commercialized by Q3 FY25, expanding capacity and product range.</li>
<li>Strong order pipeline, diversified segments (CDMO, branded generics), and high-margin segments to drive profitability.</li>
<li>Aiming for 25-30% revenue CAGR and 4-5% margin expansion in upcoming years.</li>
</ul>



Innova Captab (1605221D IN)'s New Jammu facility to be commercialized by Q3 FY25, expanding capacity and product range.
Strong order pipeline, diversified segments (CDMO, branded generics), and high-margin segments to drive profitability.
Aiming for 25-30% revenue CAGR and 4-5% margin expansion in upcoming years.


The Beat Ideas: Innova Captab Ltd, Jammu Capex Kicker, Margin Expansion

Akums Drugs and Pharmaceuticals / Equity Bottom-Up

<ul>
<li>Akums secured a €200m European supply contract, marking its first large entry into regulated markets and validating its compliance and scale capabilities.</li>
<li>This shifts Akums from a domestic CDMO leader to a credible global player, with exports positioned to become a material earnings contributor from FY27.</li>
<li>While near-term growth remains muted, Akums’ medium-term profile looks stronger, with greater diversification and reduced dependence on India’s CDMO cycle.</li>
</ul>


Akums secured a €200m European supply contract, marking its first large entry into regulated markets and validating its compliance and scale capabilities.
This shifts Akums from a domestic CDMO leader to a credible global player, with exports positioned to become a material earnings contributor from FY27.
While near-term growth remains muted, Akums’ medium-term profile looks stronger, with greater diversification and reduced dependence on India’s CDMO cycle.


Business Breakdown: Akums Drugs - Market Leader with Global Ambitions

India

Innova Captab Private Limited operates as a manufacturer of pharmaceutical product. The Company provides tablets, syrups, and capsules. Innova Captab serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Innova Captab (1605221D IN)

Innova Captab Q4FY25 Update: Jammu Plant, R&D, and Market Penetration

Innova Captab (1605221D IN) sees strong Q4 FY25 revenue growth, but new Jammu plant impacts profitability; expects significant FY26 growth with...

Sudarshan Bhandari

Innova Captab’s Jammu Expansion Update

Innova Captab opens new manufacturing facility in Jammu, boosting capacity for tablets and LVP/respules, positioning for premium exports and...

Sudarshan Bhandari

Innova Captab Limited: Q3 FY25 Update

Innova Captab's Q3 FY25 results show revenue growth, EBITDA margins improvement, and significant expansion with innovative dosage forms, setting...

Sudarshan Bhandari

The Beat Ideas: Innova Captab Ltd, Jammu Capex Kicker, Margin Expansion

Innova Captab's new Jammu facility to boost capacity and product range, driving profitability with strong order pipeline and diversified segments.

Sudarshan Bhandari

Business Breakdown: Akums Drugs - Market Leader with Global Ambitions

Akums secures €200m European supply contract, transitioning from domestic to global player with strong medium-term growth prospects.

Sudarshan Bhandari

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Innova Captab Q4FY25 Update: Jammu Plant, R&D, and Market Penetration

​Innova Captab (1605221D IN) sees strong Q4 FY25 revenue growth, but new Jammu plant impacts profitability; expects significant FY26 growth with...

Sudarshan Bhandari

Innova Captab’s Jammu Expansion Update

​Innova Captab opens new manufacturing facility in Jammu, boosting capacity for tablets and LVP/respules, positioning for premium exports and...

Sudarshan Bhandari

Innova Captab Limited: Q3 FY25 Update

​Innova Captab's Q3 FY25 results show revenue growth, EBITDA margins improvement, and significant expansion with innovative dosage forms, setting...

Sudarshan Bhandari

The Beat Ideas: Innova Captab Ltd, Jammu Capex Kicker, Margin Expansion

​Innova Captab's new Jammu facility to boost capacity and product range, driving profitability with strong order pipeline and diversified segments.

Sudarshan Bhandari

Business Breakdown: Akums Drugs - Market Leader with Global Ambitions

​Akums secures €200m European supply contract, transitioning from domestic to global player with strong medium-term growth prospects.

Sudarshan Bhandari

Innova Captab (1605221D IN) sees strong Q4 FY25 revenue growth, but new Jammu plant impacts profitability; expects significant FY26 growth with...

Innova Captab opens new manufacturing facility in Jammu, boosting capacity for tablets and LVP/respules, positioning for premium exports and...

Innova Captab's Q3 FY25 results show revenue growth, EBITDA margins improvement, and significant expansion with innovative dosage forms, setting...

Innova Captab's new Jammu facility to boost capacity and product range, driving profitability with strong order pipeline and diversified segments.

Akums secures €200m European supply contract, transitioning from domestic to global player with strong medium-term growth prospects.